– USA, MA – BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced the appointment of Arthur Tzianabos, Ph.D., president and chief scientific officer of OvaScience, Inc., to the Company’s board of directors.

“Arthur brings a valuable breadth of experience and perspective as a result of a career spanning more than 20 years, including his current leadership role at OvaScience and earlier roles leading research and development teams,” said Andrew Hirsch, president and chief executive officer, BIND Therapeutics. “His extensive experience in discovery and development of new treatments through to commercialization, portfolio management, and business development will be a valuable addition to our board as we continue expanding our pipeline and maximizing the therapeutic potential of our Accurin technology.”

“The team at BIND has developed an impressive, and pioneering, nanomedicine platform that has attracted numerous development partners and has the potential to span multiple therapeutic areas,” said Dr. Tzianabos. “I look forward to collaborating with the management team and the rest of the Board to advance BIND’s pipeline of highly selective Accurin therapies that could have a pronounced impact on the treatment of disease and the lives of many patients.”

Dr. Tzianabos currently serves as president and chief scientific officer of OvaScience, Inc., a global fertility company dedicated to improving treatment options for women around the world. Dr. Tzianabos has more than 20 years of experience in drug discovery and development, strategic planning, portfolio management, business development and alliance management. He joined OvaScience from Shire plc, where he served as senior vice president and head, Research and Nonclinical Early Development. Prior to Shire, Dr. Tzianabos was an associate professor of medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. During his time at Harvard, Dr. Tzianabos served as a consultant to several biotechnology and pharmaceutical companies, including Genzyme Corporation and Eli Lilly. Dr. Tzianabos has published more than 80 scientific papers, reviews, book chapters, and patents. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine company developing a pipeline of Accurins™, its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. BIND is leveraging its Medicinal Nanoengineering® platform to develop a pipeline of Accurins targeting hematological and solid tumors and has a number of strategic collaborations with biopharmaceutical companies to develop Accurins in areas of high unmet need. BIND’s lead drug candidate, BIND-014, is a prostate-specific membrane antigen (PSMA) -targeted Accurin that contains docetaxel, a clinically-validated and widely-used cancer chemotherapy drug. BIND-014 is currently in development for the treatment of non-small cell lung cancer, or NSCLC, in patients with KRAS mutations or squamous histology. In addition, BIND is enrolling patients in a clinical trial with BIND-014 for cervical, bladder, head and neck and cholangio cancers. BIND is also advancing BIND-510, its second PSMA-targeted Accurin drug candidate containing vincristine, a potent microtubule inhibitor with dose limiting peripheral neuropathy in its conventional form, through important preclinical studies to position it for an Investigational New Drug application filing with the U.S. Food and Drug Administration. Lastly, BIND is developing Accurins designed to inhibit PLK1 and KSP, both of which BIND believes are promising anti-mitotic targets that have been limited in the clinic due to myelotoxicity at or below therapeutic doses.

BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd., Merck & Co., or Merck (known as Merck Sharp & Dohme outside the United States and Canada) and Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals) to develop Accurins based on their proprietary therapeutic payloads and/or targeting ligands. BIND’s collaboration with AstraZeneca has resulted in FDA clearance to begin clinical trials with the Aurora B Kinase inhibitor Accurin AZD2811, which will be the second Accurin candidate to enter clinical development.

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

here the original post =>

Comments are closed.